Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR2 Fusions”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Not applicableStudy completedNCT02762721
What this trial is testing

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Who this might be right for
Intrahepatic CholangiocarcinomaMixed Hepatocellular CholangiocarcinomaCholangiocarcinoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 131
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Looking for participantsNCT05678270
What this trial is testing

ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd. 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05174650
What this trial is testing

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Who this might be right for
Intrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 27
Testing effectiveness (Phase 2)Study completedNCT02265341
What this trial is testing

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Who this might be right for
Malignant Hepatobiliary Neoplasm
Mayo Clinic 12
Large-scale testing (Phase 3)Looking for participantsNCT04353375
What this trial is testing

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Advanced Intrahepatic CholangiocarcinomaSolid Tumor, Adult
Hutchmed 235
Testing effectiveness (Phase 2)Study completedNCT04238715
What this trial is testing

E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Who this might be right for
Cholangiocarcinoma
Eisai Co., Ltd. 63
Not applicableStudy completedNCT02450123
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT07786766
What this trial is testing

Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

Who this might be right for
Biliary Tract Cancer (BTC)
Haitao Zhao, MD 154
Testing effectiveness (Phase 2)Study completedNCT04526106
What this trial is testing

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Who this might be right for
FGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/Rearrangement+5 more
Elevar Therapeutics 490
Testing effectiveness (Phase 2)Looking for participantsNCT06439485
What this trial is testing

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer Center 25